Bris­tol-My­ers in­vites J&J in­to an al­liance of gi­ants on car­dio drug de­vel­op­ment/com­mer­cial­iza­tion pro­gram

J&J $JNJ has jumped in­to a part­ner­ship with Bris­tol-My­ers Squibb $BMY on an ear­ly-stage car­dio drug.

In an un­usu­al al­liance of gi­ants, J&J is pay­ing an un­spec­i­fied amount of cash to part­ner with Bris­tol-My­ers on BMS-986177, a Fac­tor XIa in­hibitor be­ing de­vel­oped as an an­ti­co­ag­u­lant to pre­vent throm­bot­ic events.

The phar­ma play­ers plan to joint­ly com­mit cash and ex­per­tise to a “broad” de­vel­op­ment pro­gram cov­er­ing mul­ti­ple in­di­ca­tions and then share any prof­its that come out of the work. And they’re work­ing on ob­ser­va­tions that beat­ing back the lev­el of throm­bin can re­duce the risk of heart at­tack, stroke and pe­riph­er­al artery dis­ease. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER